NEW YORK (AP) -- Medical and industrial instruments maker Danaher said Monday it agreed to buy medical testing instrument maker Beckman Coulter for about $5.8 billion.
Beckman Coulter, which is based on Brea, California, makes products that simplify and automate biomedical testing. It will become part of Danaher's life sciences and diagnostics business if the deal goes through. That would make the life sciences unit Danaher's largest.
Danaher has agreed to pay $83.50 per Beckman Coulter share, a 45 percent premium over its share price on Dec. 9 -- the day before acquisition rumors first surfaced. Danaher valued the purchase at $6.8 billion including Beckman Coulter's debt and its cash on hand.
The deal is expected to be completed in the first half of the year. Closing depends on a majority of Beckman Coulter shareholders tendering their shares in favor of the deal. Beckman Coulter said its board unanimously supports the sale.
Shares of Beckman Coulter surged $7.53, or 10 percent, to $82.70 in pre-market trading. Danaher shares rose $1.31, or 2.7 percent, to $49.29.
Danaher, which is based in Washington, D.C., reported $13.2 billion in revenue in 2010, with $2.3 billion from the life sciences business. Beckman Coulter has not reported its full-year results, but it had $2.68 billion in revenue in the first nine months of the year.
Beckman Coulter has dealt with several recent setbacks. The company said in March is would have to get new regulatory approval for its AccuTnl test kit, which is used to determine is a patient has suffered a heart attack. The Food and Drug Administration said it appeared the company made changes to the test kits without approval July. It reported a drop in its second-quarter profit and cut its annual guidance because sales from developed markets were down. Chairman, CEO and President Scott Garrett resigned unexpectedly in September after five years with the company.
In December, Beckman Coulter was linked to potential acquirers including Blackstone Group LP and Apollo Global Management LLC.
The company's shares have traded between $43.95 and $78.27 in the last year.
Beckman Coulter, which is based on Brea, California, makes products that simplify and automate biomedical testing. It will become part of Danaher's life sciences and diagnostics business if the deal goes through. That would make the life sciences unit Danaher's largest.
Danaher has agreed to pay $83.50 per Beckman Coulter share, a 45 percent premium over its share price on Dec. 9 -- the day before acquisition rumors first surfaced. Danaher valued the purchase at $6.8 billion including Beckman Coulter's debt and its cash on hand.
The deal is expected to be completed in the first half of the year. Closing depends on a majority of Beckman Coulter shareholders tendering their shares in favor of the deal. Beckman Coulter said its board unanimously supports the sale.
Shares of Beckman Coulter surged $7.53, or 10 percent, to $82.70 in pre-market trading. Danaher shares rose $1.31, or 2.7 percent, to $49.29.
Danaher, which is based in Washington, D.C., reported $13.2 billion in revenue in 2010, with $2.3 billion from the life sciences business. Beckman Coulter has not reported its full-year results, but it had $2.68 billion in revenue in the first nine months of the year.
Beckman Coulter has dealt with several recent setbacks. The company said in March is would have to get new regulatory approval for its AccuTnl test kit, which is used to determine is a patient has suffered a heart attack. The Food and Drug Administration said it appeared the company made changes to the test kits without approval July. It reported a drop in its second-quarter profit and cut its annual guidance because sales from developed markets were down. Chairman, CEO and President Scott Garrett resigned unexpectedly in September after five years with the company.
In December, Beckman Coulter was linked to potential acquirers including Blackstone Group LP and Apollo Global Management LLC.
The company's shares have traded between $43.95 and $78.27 in the last year.